Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-03-24

Clinical Trial Update: Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating 0.3% Hypromellose Eyedrops for efficacy and tolerability in patients undergoing LASIK; results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • 0.3% Hypromellose Eyedrops (hypromellose)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Dry Eye | Phase 4 | Status: COMPLETED | Results posted: 2011-03-24